An antibody-drug combination called Brentuximab Vedotin is commonly known as Adcetris. It may combine an anti-CD30 antibody with monomethyl auristatin E medication. It is an anti-neoplastic substance in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. The first approval of brentuximab vedotin occurred in 2011. A boxed advice of progressive multifocal leukoencephalopathy […]
